Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Blood (2024) 144 (Supplement 1): 769.

https://doi.org/10.1182/blood-2024-193308

Published: 2024

Journal Articles

Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial

Blood (2024) 144 (Supplement 1): 364.

https://doi.org/10.1182/blood-2024-194768

Published: 2024

Journal Articles

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Blood (2021) 138 (Supplement 1): 463.

https://doi.org/10.1182/blood-2021-145097

Published: 2021

Journal Articles

Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

Blood (2020) 136 (Supplement 1): 21–23.

https://doi.org/10.1182/blood-2020-134827

Published: 2020

Journal Articles

Results from a Prospective Real World Study Show Strong Efficacy of Idelalisib in CLL, Including High-Risk CLL, and Provide Evidence That Pjp Prophylaxis Positively Impacts on Overall Survival

Manuela Hoechstetter, MD, Philipp Eissmann, Nike Hucke, Anna van Troostenburg, Heribert Ramroth, Wolfgang Knauf

Blood (2018) 132 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2018-99-112843

Published: 2018

Journal Articles

Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

Blood (2018) 132 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2018-99-113284

Published: 2018

Journal Articles

Interim Results of the Observational Study Caro: Twice Weekly Carfilzomib Is a Convenient Treatment Option for Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

Wolfgang Knauf, Andreas Ammon, Jens Uhlig, Marie Merling, Hans-Juergen Hurtz, Corinne Vannier, Holger Schulz, Norbert Marschner, Tamara Riedt, PhD, Karin Potthoff

Blood (2018) 132 (Supplement 1): 5662.

https://doi.org/10.1182/blood-2018-99-117996

Published: 2018

Journal Articles

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Veronique Leblond, Guy Cantin, MD, Agostino Cortelezzi, Prof, Wolfgang Knauf, Mourad Tiab, Mehmet Turgut, MD, Andrey Zaritskey, Jean-Louis Merot, Kerstin Trunzer, Susan Robson, Ekaterina Gresko, Stephan Stilgenbauer, MD PhD, Robin Foà, Francesc Bosch

Blood (2017) 130 (Supplement 1): 3015.

https://doi.org/10.1182/blood.V130.Suppl_1.3015.3015

Published: 2017

Journal Articles

Multicenter Phase II Trial of Bendamustine, Lenalidomide and Dexamethasone (BRd) As 2 nd -Line Therapy for Multiple Myeloma

Blood (2014) 124 (21): 4779.

https://doi.org/10.1182/blood.V124.21.4779.4779

Published: 2014

Journal Articles

Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study

Martin Kropff, MD, Martin Vogel, MD PhD, Andrea Kreter, Dipl. Stat., Rudolf Schlag, Lothar Müller, MD, Rudolf Weide, MD, Wolfgang Knauf, MD PhD, Thomas Decker, MD, Heinrich Fiechtner, PhD, Georgi Kojouharoff, MD, Stephan Kremers, MD, Wolfgang E Berdel, MD

Blood (2014) 124 (21): 3470.

https://doi.org/10.1182/blood.V124.21.3470.3470

Published: 2014

Journal Articles

1 st -Line Treatment with R-CHOP-14 or R-CHOP-21 in Patients with High-Grade Non-Hodgkin’s Lymphoma Is Similarly Effective: Data from the German Prospective TLN Registry

Wolfgang Knauf, MD PhD, Wolfgang Abenhardt, MD, Johannes Mohm, MD, Jacqueline Rauh, MD, Renate Grugel, Johanna Harde, Martina Jänicke, PhD, Norbert Marschner, MD

Blood (2014) 124 (21): 4406.

https://doi.org/10.1182/blood.V124.21.4406.4406

Published: 2014

Journal Articles

Response To 1 st -Line Treatment With BR Or FCR In Patients With Chronic Lymphocytic Leukaemia: First Outcome Data From The German Prospective TLN Registry

Wolfgang Knauf, MD, Wolfgang Abenhardt, MD, Erik Engel, Renate Grugel, Johanna Harde, Norbert Marschner, MD

Blood (2013) 122 (21): 4181.

https://doi.org/10.1182/blood.V122.21.4181.4181

Published: 2013

Journal Articles

Response To 1 st -Line Treatment With BR Or R-CHOP In Patients With Indolent Non-Hodgkin’s Lymphoma: First Outcome Data From The German Prospective TLN Registry

Wolfgang Knauf, MD, Wolfgang Abenhardt, MD, Richard Hansen, MD, Renate Grugel, Johanna Harde, Norbert Marschner, MD

Blood (2013) 122 (21): 3036.

https://doi.org/10.1182/blood.V122.21.3036.3036

Published: 2013

Journal Articles

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial

Blood (2012) 119 (21): 4851–4859.

https://doi.org/10.1182/blood-2011-09-378505

Published: 2012

Includes: Supplemental data

Journal Articles

How to Treat Chronic Lymphocytic Leukemia? Data From a Clinical Registry by Office-Based Hematologists in Germany (TLN Registry)

Wolfgang Knauf, MD, Wolfgang Abenhardt, MD, Ali Aldaoud, MD, Christian Lerchenmüller, MD, Michaela Koska, Norbert Marschner, MD

Blood (2011) 118 (21): 4606.

https://doi.org/10.1182/blood.V118.21.4606.4606

Published: 2011

Journal Articles

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)

Mathias J Rummel, Ulrich von Gruenhagen, Norbert Niederle, Harald Ballo, Eckhart Weidmann, Manfred Welslau, Gerhard Heil, Christina Balser, Heinz A Duerk, Martina Stauch, Dorothea Kofahl-Krause, Ulrich Kaiser, Wolfgang Knauf, Wolfram Brugger, MD

Blood (2008) 112 (11): 2596.

https://doi.org/10.1182/blood.V112.11.2596.2596

Published: 2008

Journal Articles

High Complete Remission Rate in Patients with Acute Myeloid Leukemia (AML) above the Age of 60 Years: A Report of the AML97#38 Study of the East German Hematology and Oncology Study Group.

Blood (2004) 104 (11): 880.

https://doi.org/10.1182/blood.V104.11.880.880

Published: 2004

Journal Articles

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation

Jochen Casper, Wolfgang Knauf, Thomas Kiefer, Daniel Wolff, Beate Steiner, Ulrich Hammer, Rudolf Wegener, Hans-Dieter Kleine, Stefan Wilhelm, Agnes Knopp, Gernot Hartung, Gottfried Dölken, Mathias Freund

Blood (2004) 103 (2): 725–731.

https://doi.org/10.1182/blood-2002-11-3615

Published: 2004

Journal Articles

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

Dieter Huhn, Christoph von Schilling, Martin Wilhelm, Anthony D. Ho, Michael Hallek, Rolf Kuse, Wolfgang Knauf, Ute Riedel, Axel Hinke, Stefanie Srock, Stefan Serke, Christian Peschel, Bertold Emmerich

Blood (2001) 98 (5): 1326–1331.

https://doi.org/10.1182/blood.V98.5.1326

Published: 2001

Journal Articles

Elevated Serum Thymidine Kinase Levels Identify a Subgroup at High Risk of Disease Progression in Early, Nonsmoldering Chronic Lymphocytic Leukemia

Michael Hallek, Irmgard Langenmayer, Christoph Nerl, Wolfgang Knauf, Hermann Dietzfelbinger, Dagmar Adorf, Marianne Ostwald, Raymonde Busch, Ingrid Kuhn-Hallek, Eckhard Thiel, Bertold Emmerich

Blood (1999) 93 (5): 1732–1737.

https://doi.org/10.1182/blood.V93.5.1732

Published: 1999

NARROW

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

Results from a Prospective Real World Study Show Strong Efficacy of Idelalisib in CLL, Including High-Risk CLL, and Provide Evidence That Pjp Prophylaxis Positively Impacts on Overall Survival

Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

Interim Results of the Observational Study Caro: Twice Weekly Carfilzomib Is a Convenient Treatment Option for Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Multicenter Phase II Trial of Bendamustine, Lenalidomide and Dexamethasone (BRd) As 2 nd -Line Therapy for Multiple Myeloma

Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study

1 st -Line Treatment with R-CHOP-14 or R-CHOP-21 in Patients with High-Grade Non-Hodgkin’s Lymphoma Is Similarly Effective: Data from the German Prospective TLN Registry

Response To 1 st -Line Treatment With BR Or FCR In Patients With Chronic Lymphocytic Leukaemia: First Outcome Data From The German Prospective TLN Registry

Response To 1 st -Line Treatment With BR Or R-CHOP In Patients With Indolent Non-Hodgkin’s Lymphoma: First Outcome Data From The German Prospective TLN Registry

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial

How to Treat Chronic Lymphocytic Leukemia? Data From a Clinical Registry by Office-Based Hematologists in Germany (TLN Registry)

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)

High Complete Remission Rate in Patients with Acute Myeloid Leukemia (AML) above the Age of 60 Years: A Report of the AML97#38 Study of the East German Hematology and Oncology Study Group.

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

Elevated Serum Thymidine Kinase Levels Identify a Subgroup at High Risk of Disease Progression in Early, Nonsmoldering Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only